IGKV2D-29 and Parkinson disease: Indeed, the identification of postsynaptic A2A/D2 receptor interactions in the striatum together with the findings that A2A receptor antagonists are neuroprotective in Parkinson’s disease models [18] and increase dopamine synthesis from L-DOPA [72], led to the proposal for the use of A2A receptor antagonists in Parkinson ́s disease.